Nord/Est/Ile-de-France Neuromuscular Diseases Reference Center, Institut de Myologie, Pitié-Salpêtrière Hospital, APHP, 47-83 Bd de L'Hôpital, 75013, Paris, France.
Azienda Ospedaliera Universitaria Sant'Andrea, Rome, Italy.
J Neurol. 2024 Jul;271(7):4008-4018. doi: 10.1007/s00415-024-12298-0. Epub 2024 Mar 22.
X-linked myopathy with excessive autophagy (XMEA) linked to the VMA21 gene leads to autophagy failure with progressive vacuolation and atrophy of skeletal muscles. Current knowledge of this rare disease is limited. Our objective was to define the clinical, radiological, and natural history of XMEA.
We conducted a retrospective study collecting clinical, genetic, muscle imaging, and biopsy data of XMEA patients followed in France and reviewed the literature for additional cases.
Eighteen males had genetically confirmed XMEA in France, carrying four different VMA21 variants. Mean age at disease onset was 9.4 ± 9.9 (range 1-40) years. In 14/18 patients (77.8%), onset occurred during childhood (< 15 years); however in four patients, the disease started in adulthood. Patients had anterior and medial compartment thigh muscle weakness, distal contractures (56.3%), elevated CK levels (1287.9 ± 757.8 U/l) and autophagic vacuoles with sarcolemmal features on muscle histopathology. Muscle MRI (n = 10) showed a characteristic pattern of lower limb muscle involvement. In 11 patients, outcome measures were available for an average follow-up period of 10.6 ± 9.8 years and six of them show disease progression. Mean change of functional outcomes was 0.5 ± 1.2 points for Brooke and 2.2 ± 2.5 points for Vignos score, 7/16 patients (43.8%) needed a walking aid and 3/16 (18.8%) were wheelchair-bound (median age of 40 years old, range 39-48). The variant c.164-7 T > G was associated with a later onset of symptoms. Respiratory insufficiency was common (57.1%) but cardiac involvement rare (12.5%).
XMEA has variable age of onset, but a characteristic clinical, histopathological, and muscle imaging presentation, guiding the diagnosis. Although slowly, motor disability progresses with time, and relevant genotype-phenotype correlations will help design future clinical trials.
X 连锁肌病伴过度自噬(XMEA)与 VMA21 基因相关,导致自噬失败,伴骨骼肌进行性空泡化和萎缩。目前对这种罕见疾病的认识有限。我们的目的是定义 XMEA 的临床、放射学和自然病史。
我们进行了一项回顾性研究,收集了在法国接受治疗的 XMEA 患者的临床、遗传、肌肉影像学和活检数据,并查阅了文献中的其他病例。
法国有 18 名男性经基因证实患有 XMEA,携带四种不同的 VMA21 变异。疾病发病的平均年龄为 9.4±9.9 岁(范围 1-40 岁)。在 18 名患者中(77.8%),14 名(77.8%)在儿童期(<15 岁)发病;然而,有 4 名患者在成年期发病。患者存在前内侧大腿肌肉无力、远端挛缩(56.3%)、肌酸激酶水平升高(1287.9±757.8 U/l)和肌活检中的具有肌膜特征的自噬空泡。肌肉 MRI(n=10)显示下肢肌肉受累的特征性模式。在 11 名患者中,获得了平均随访 10.6±9.8 年的结局测量值,其中 6 名患者的疾病进展。Brooke 和 Vignos 评分的功能结局平均变化分别为 0.5±1.2 分和 2.2±2.5 分,16 名患者中有 7 名(43.8%)需要助行器,16 名患者中有 3 名(18.8%)需要轮椅(中位数年龄为 40 岁,范围 39-48 岁)。c.164-7T>G 变异与症状出现较晚有关。呼吸功能不全很常见(57.1%),但心脏受累罕见(12.5%)。
XMEA 的发病年龄不同,但具有特征性的临床、组织病理学和肌肉影像学表现,有助于诊断。尽管进展缓慢,但随着时间的推移,运动功能障碍会逐渐进展,相关的基因型-表型相关性将有助于设计未来的临床试验。